News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,065 Results
Type
Article (43691)
Company Profile (473)
Press Release (693889)
Multimedia
Podcasts (123)
Webinars (20)
Section
Business (209325)
Career Advice (2038)
Deals (36152)
Drug Delivery (119)
Drug Development (83976)
Employer Resources (174)
FDA (16688)
Job Trends (15186)
News (354163)
Policy (33276)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2655)
Accelerated approval (34)
Adcomms (28)
Allergies (144)
Alliances (51121)
ALS (178)
Alzheimer's disease (1725)
Antibody-drug conjugate (ADC) (326)
Approvals (16923)
Artificial intelligence (542)
Autoimmune disease (157)
Automation (38)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (192)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (60)
Breast cancer (647)
Cancer (4913)
Cardiovascular disease (418)
Career advice (1723)
Career pathing (37)
CAR-T (291)
CDC (46)
Celiac Disease (2)
Cell therapy (778)
Cervical cancer (36)
Clinical research (71428)
Collaboration (1791)
Company closure (4)
Compensation (1173)
Complete response letters (63)
COVID-19 (2772)
CRISPR (96)
C-suite (873)
Cystic fibrosis (152)
Data (6292)
Decentralized trials (2)
Denatured (39)
Depression (142)
Diabetes (504)
Diagnostics (6745)
Digital health (48)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (267)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (243)
Earnings (91367)
Editorial (59)
Employer branding (21)
Employer resources (153)
Events (120977)
Executive appointments (1002)
FDA (19829)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1530)
Gene editing (211)
Generative AI (45)
Gene therapy (644)
GLP-1 (1010)
Government (4756)
Grass and pollen (6)
Guidances (384)
Healthcare (19203)
HIV (59)
Huntington's disease (46)
IgA nephropathy (85)
Immunology and inflammation (274)
Immuno-oncology (61)
Indications (107)
Infectious disease (3040)
Inflammatory bowel disease (197)
Inflation Reduction Act (17)
Influenza (116)
Intellectual property (250)
Interviews (315)
IPO (16933)
IRA (52)
Job creations (3712)
Job search strategy (1439)
JPM (66)
Kidney cancer (15)
Labor market (83)
Layoffs (581)
Leadership (32)
Legal (8025)
Liver cancer (93)
Longevity (14)
Lung cancer (664)
Lymphoma (380)
Machine learning (43)
Management (59)
Manufacturing (810)
MASH (170)
Medical device (13914)
Medtech (13967)
Mergers & acquisitions (20297)
Metabolic disorders (1319)
Multiple sclerosis (165)
NASH (19)
Neurodegenerative disease (338)
Neuropsychiatric disorders (96)
Neuroscience (3012)
Neurotech (1)
NextGen: Class of 2026 (6772)
Non-profit (4581)
Now hiring (66)
Obesity (632)
Opinion (281)
Ovarian cancer (167)
Pain (204)
Pancreatic cancer (229)
Parkinson's disease (294)
Partnered (34)
Patents (494)
Patient recruitment (493)
Peanut (57)
People (60294)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22471)
Phase 2 (31494)
Phase 3 (23277)
Pipeline (5263)
Policy (295)
Postmarket research (2602)
Preclinical (9609)
Press Release (67)
Prostate cancer (245)
Psychedelics (56)
Radiopharmaceuticals (297)
Rare diseases (889)
Real estate (6064)
Recruiting (71)
Regulatory (24981)
Reports (52)
Research institute (2484)
Resumes & cover letters (353)
Rett syndrome (27)
RNA editing (21)
RSV (76)
Schizophrenia (154)
Series A (254)
Series B (202)
Service/supplier (11)
Sickle cell disease (103)
Special edition (26)
Spinal muscular atrophy (162)
Sponsored (42)
Startups (3807)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (82)
Vaccines (1024)
Venture capital (95)
Weight loss (409)
Women's health (91)
Worklife (19)
Date
Today (145)
Last 7 days (629)
Last 30 days (2263)
Last 365 days (30781)
2026 (3227)
2025 (31067)
2024 (36298)
2023 (41015)
2022 (52277)
2021 (56764)
2020 (54920)
2019 (47417)
2018 (35696)
2017 (33027)
2016 (32348)
2015 (38397)
2014 (32189)
2013 (27110)
2012 (29222)
2011 (29866)
2010 (27996)
Location
Africa (754)
Alabama (89)
Alaska (7)
Arizona (317)
Arkansas (14)
Asia (40701)
Australia (6760)
California (11441)
Canada (3291)
China (1137)
Colorado (486)
Connecticut (492)
Delaware (336)
Europe (89201)
Florida (1680)
Georgia (357)
Hawaii (3)
Idaho (61)
Illinois (879)
India (65)
Indiana (522)
Iowa (24)
Japan (432)
Kansas (129)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1400)
Massachusetts (8328)
Michigan (323)
Minnesota (635)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (121)
New Hampshire (83)
New Jersey (3044)
New Mexico (31)
New York (2995)
North Carolina (1527)
North Dakota (9)
Northern California (5560)
Ohio (336)
Oklahoma (21)
Oregon (45)
Pennsylvania (2295)
Puerto Rico (23)
Rhode Island (48)
South America (1121)
South Carolina (65)
South Dakota (1)
Southern California (4435)
Tennessee (174)
Texas (1763)
United States (40705)
Utah (340)
Vermont (1)
Virginia (266)
Washington D.C. (82)
Washington State (953)
West Virginia (4)
Wisconsin (113)
Wyoming (2)
738,065 Results for "sirna therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next‑Generation Obesity Therapy
• Vial’s INHBE siRNA is a first‑in‑class, liver‑targeted (GalNAc‑conjugated) siRNA therapy that silences INHBE and its gene product, Activin E • Leading key opinion leaders (KOLs) Drs. Jason Fung, Scott Kahan, Lawrence Cheskin, and Lee Kaplan from leading institutions such as Johns Hopkins, GMU, and Dartmouth University respectively shared their insights on challenges with current GLP-1 treatments as well as the potential benefits of INHBE siRNA therapies like Vial’s • INHBE siRNAs are designed to deliver fat-selective weight loss while preserving lean muscle mass • Vial’s INHBE siRNA will be investigated for its potential as both a mono-therapy and in combination with GLP-1s to offer patients flexibility on their weight loss journey
December 16, 2025
·
1 min read
Press Releases
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
December 16, 2025
·
1 min read
Press Releases
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
January 8, 2026
·
6 min read
Deals
Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program
Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, a group of neurodegenerative disorders including Parkinson’s disease.
September 2, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
February 11, 2026
·
10 min read
Press Releases
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues
December 18, 2025
·
2 min read
Press Releases
Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction
December 18, 2025
·
2 min read
Press Releases
Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity
◆ VIAL-INHBE is a novel, GalNAc-conjugated INHBE (Activin E) siRNA for the treatment of obesity and other cardiometabolic indications with a projected Q6M dosing intervall ◆ VIAL-INHBE DIO mouse model data demonstrated compelling fat-selective weight-loss and lean mass preservation ◆ Combination therapy with a low-dose GLP-1 resulted in synergistic weight loss and lean mass preservation that was maintained off-GLP-1 treatment ◆ A Phase 1 open-label study in Australia is initiating to evaluate safety, pharmacokinetics, and pharmacodynamic responses ◆ Interim subcutaneous safety and pharmacokinetic data are expected in H1 2026
October 23, 2025
·
1 min read
Press Releases
Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNA
December 3, 2025
·
3 min read
Press Releases
Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)
February 6, 2026
·
5 min read
1 of 73,807
Next